Terle Preston M, Peebles Liam A, Verma Arjun, Kraeutler Matthew J
Tulane University School of Medicine, New Orleans, Lougisiana, U.S.A..
Tulane University School of Medicine, New Orleans, Lougisiana, U.S.A.
Arthroscopy. 2025 Jun;41(6):2105-2113. doi: 10.1016/j.arthro.2024.07.032. Epub 2024 Aug 13.
To provide a summary of available literature on the minimal clinically important difference (MCID), substantial clinical benefit (SCB), and patient acceptable symptom state (PASS) after hip arthroscopy for femoroacetabular impingement (FAI).
A systematic review was conducted via the Cochrane Library, PubMed, Ovid MEDLINE, and Embase to identify studies that calculated MCID, SCB, or PASS for patient-reported outcome measures after hip arthroscopy for FAI. The electronic search strategy used was as follows: hip AND arthroscopy AND (MCID OR "minimal clinically important difference" OR SCB OR "substantial clinical benefit" OR PASS OR "patient acceptable symptom state"). Inclusion criteria were English-language studies published from 1980 to 2023 reporting clinical outcome scores and calculated values of MCID, PASS, or SCB for patients undergoing hip arthroscopy for FAI.
Forty-two studies (5 Level II, 19 Level III, and 18 Level IV) met inclusion and exclusion criteria. The most commonly used outcome measures across MCID, SCB, and PASS were the Hip Outcome Score sports-specific subscale and the activities of daily living subscale, the modified Harris Hip Score, and the 12-item international Hip Outcome Tool. The range of MCID values for Hip Outcome Score sports-specific subscale, Hip Outcome Score activities of daily living subscale, modified Harris Hip Score, and 12-item international Hip Outcome Tool were 7.2-15.7, 7.3-15.4, 7.2-16.8, and 8.8-16.2 respectively. Similarly, for SCB the values ranged from 77.9-96.9, 90.4-98.5, 20.0-98.4, and 66.7-87.5, respectively. Lastly, the PASS values ranged from 63.9-80.9, 85.9-99.2, 74.0-97.0, and 59.5-86.0, respectively.
MCID, SCB, and PASS values for patient-reported outcome measures after hip arthroscopy for the management of FAI are highly dependent on their associated study including study population and calculation methods.
IV, systematic review of Level II-IV studies.
总结关于髋关节镜治疗股骨髋臼撞击症(FAI)后最小临床重要差异(MCID)、显著临床获益(SCB)和患者可接受症状状态(PASS)的现有文献。
通过Cochrane图书馆、PubMed、Ovid MEDLINE和Embase进行系统综述,以识别计算髋关节镜治疗FAI后患者报告结局指标的MCID、SCB或PASS的研究。使用的电子检索策略如下:髋关节 AND 关节镜检查 AND(MCID 或“最小临床重要差异”或 SCB 或“显著临床获益”或 PASS 或“患者可接受症状状态”)。纳入标准为1980年至2023年发表的英文研究,报告临床结局评分以及髋关节镜治疗FAI患者的MCID、PASS或SCB计算值。
42项研究(5项II级、19项III级和18项IV级)符合纳入和排除标准。MCID、SCB和PASS中最常用的结局指标是髋关节结局评分运动特定子量表和日常生活活动子量表、改良Harris髋关节评分以及12项国际髋关节结局工具。髋关节结局评分运动特定子量表、髋关节结局评分日常生活活动子量表、改良Harris髋关节评分和12项国际髋关节结局工具的MCID值范围分别为7.2 - 15.7、7.3 - 15.4、7.2 - 16.8和8.8 - 16.2。同样,SCB值分别为77.9 - 96.9、90.4 - 98.5、20.0 - 98.4和66.7 - 87.5。最后,PASS值分别为63.9 - 80.9、85.9 - 99.2、74.0 - 97.0和59.5 - 86.0。
髋关节镜治疗FAI后患者报告结局指标的MCID、SCB和PASS值高度依赖于其相关研究,包括研究人群和计算方法。
IV,II - IV级研究的系统综述。